LIC provides another opportunity to revive lapsed policies
Updated:
Updated:
January 08, 2021 00:09 IST
It has also authorised its 1,526 satellite offices to revive policies where special medical tests are not required.
Share Article
AAA
It has also authorised its 1,526 satellite offices to revive policies where special medical tests are not required.
To encourage individuals to continue their risk cover amid the coronavirus pandemic, LIC on Thursday launched a campaign where lapsed policies can be revived. The insurance behemoth has launched a Special Revival Campaign starting from January 7 till March 6 for its customers to revive their lapsed individual policies subject to certain conditions.
Nostra Terra Oil and Gas completes oversubscribed fundraise
08 Jan 2021
AIM-listed
Nostra Terra, the oil & gas exploration and production company with a portfolio of development and production assets in Texas, USA, has announced completion of an
oversubscribed fundraise of £500,000 with institutional and professional investors.
Nostra Terra stated strategy includes; growing production from existing assets in the Permian Basin and Pine Mills, increase cashflow from production growth, and acquisitions when suitable. Over recent months the Company has delivered on that with the farmout of an undrilled portion of Pine Mills, the acquisition of the Caballos Creek asset in South Texas, and the farmin to the additional asset in the Permian Basin.
Indian equity markets plunged over 40 per cent from January highs to a four-year low on March 24 when a nationwide lockdown triggered a panic that earnings would collapse as businesses shuttered. Foreign investors, mutual funds and individual retail investors fled in March and April fearing the worst.
AIM-listed Baron Oil has provided shareholders with an update on the Chuditch PSC, offshore Timor-Leste. Technical work completed to date indicates an aggregate gross Mean recoverable prospective resource of greater than 3,500 BCF of gas (more than 580 MMBOE).
DGAP-News: CEVEC Pharmaceuticals GmbH: CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy
CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy
08.01.2021 / 12:00
CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA
(R) in gene therapy
(R) Technology for manufacturing of gene therapy products
ELEVECTA
Cologne, Germany, January 8, 2021
CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of a license agreement with Biogen Inc. (Biogen; Nasdaq: BIIB) for the use of CEVEC s proprietary ELEVECTA
(R) Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.